Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.

"Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look forward to the results of the Canadian/European trial (MAESTRO-01) in the second half of this year," said Kevin Giese, President and CEO of BioMS Medical. "Our hope is that the results of this trial will confirm that dirucotide is able to significantly slow the progression of MS, specifically in patients with secondary progressive multiple sclerosis."

Currently, BioMS is conducting two clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

        -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
           phase III trial, being conducted in Canada and Western Europe, had
           completed full recruitment of 611 SPMS patients at 47 trial sites
           in ten countries. To date, there have been nine positive safety
           reviews from the Data Safety Monitoring Board (DSMB). The primary
           clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a
           statistically and clinically significant increase in the time to
           progression of the disease as measured by the Expanded Disability
           Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4
           immune response genes.

           On August 13, 2008, the DSMB conducted a scheduled interim
           analysis of efficacy and safety and recommended that the trial
           continue to completion. The interim analysis evaluated the first
           200 patients to complete MAESTRO-01 and assessed the likelihood of
           the study reaching
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... 17 Digital Union announced today they,have entered ... (Southeast,Regional Genetics Group) in Region 3 to provide ... states, Puerto Rico and the,US Virgin Islands. The ... has received additional funding for another five-year period.,With ...
... Technologies and ... Decade, ST. LOUIS, Aug. 17 Monsanto Company ... Biosafety,Technical Committee (CTNBio) approved the company,s MON 810 insect,protection ... Borer,for future commercial use in corn in Brazil. ...
... The Foundation,for Taxpayer and Consumer Rights (FTCR) today praised ... Interstate Alliance for Stem Cell,Research to the public saying ... science. The decision came after a closed,session of the ... Warren Wollschlager, of the Connecticut Department of Health and ...
Cached Biology Technology:Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait 2Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... German . Waiting: a clever move! , ... prominent ,Stanford Marshmallow Experiment,: the children were presented with a marshmallow ... and receive a second one if the first one was still ... were able to wait for the delayed reward showed greater success ...
... Conn. , March 13, 2013 /PRNewswire-iReach/ -- ... and biologics will need to address the current ... innovative ideas for developing antibodies against intracellular and ... for infectious disease and CNS applications. The versatility ...
... household pesticide contamination emphasizes the need for less ... blocking cracks where insects can enter and other ... concluded. Their study appears in the ACS, journal ... Lu and colleagues cite previous studies showing that ...
Cached Biology News:Doing business with a parrot 2Engineering Stream Conferences at PEGS 2013 2Engineering Stream Conferences at PEGS 2013 3
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... an early protein. Can ... post-infection exhibiting an intranuclear inclusion ... between 6-24 hours. These ... granular staining. No other ...
Biology Products: